Navigation Links
AccuVein Achieves Quality System Milestone
Date:7/27/2009

COLD SPRING HARBOR, N.Y., July 27 /PRNewswire/ -- AccuVein LLC, maker of the AV300, the world's first hand-held, non-contact vein illumination device, today announced that its quality system has received an International Organization for Standardization (ISO) 13485 Certification. This certifies to customers around the globe AccuVein's commitment to the quality and safety of its medical device design, development, production, installation and delivery procedures.

The quality system was further designed to meet U.S. FDA Good Manufacturing Practices (cGMP) requirements. AccuVein has begun shipping the AV300 in the U.S. and recently announced agreements with two large group purchasing organizations. In addition the AV300 is available on the General Services Administration Schedule, bringing the AccuVein AV300 to blood centers, hospitals, and government-affiliated institutions across the nation.

"AccuVein launched the AV300 to help healthcare professionals locate hard-to-find veins and is committed to ensuring its products are of the highest quality while meeting healthcare provider and patient needs," said Stephen P. Conlon, President of AccuVein. "Receipt of this approval from BSI, an objective and accredited organization, is a critical step forward in our path to deliver the AV300 to healthcare practitioners around the globe."

To achieve this three-year certification, AccuVein had to demonstrate that their quality system conforms to the exacting customer and regulatory standards of the ISO. ISO 13485:2003 is specifically designed for regulatory compliance of medical device companies. It supplements ISO 9001 with additional requirements including process control, design control, retention of records, accountability, traceability, and customer satisfaction.

AccuVein achieved this key milestone following a careful assessment of their quality management system by BSI Group, a global provider of management systems assessment, certification and training services, with more than 60,000 certified locations and clients in over 100 countries. AccuVein's quality system meets ISO standard and U.S. FDA Good Manufacturing Practices requirements.

For a copy of AccuVein's ISO 13485:2003 certificate, please visit www.AccuVein.com/quality.

About AccuVein

AccuVein applies advanced technologies to important healthcare challenges. Their innovative AV300 allows practitioners to see a map on the patient's skin of the position of peripheral veins, helping caregivers locate these veins while they perform the most common invasive medical procedure - venipuncture. Built using AccuVein's expertise in medical device miniaturization and user-intuitive design, the AV300 is the world's first portable, non-contact vein illumination solution. With more than a dozen patents filed worldwide, AccuVein demonstrates an ongoing commitment to invest in improving patient care and patient satisfaction.

For more information on the AccuVein AV300, please visit www.AccuVein.com.

About BSI

BSI Group is a global provider of management systems assessment, certification and training services, with more than 60,000 certified locations and clients in over 100 countries.

    Contacts:

    For Media Inquiries:
    Jennifer Seelin
    Makovsky + Company
    212-508-9610
    jseelin@makovsky.com

    For Sales Inquiries:
    Joe McCormick
    AccuVein LLC
    888-909-8888
    joe.mccormick@accuvein.com


'/>"/>
SOURCE AccuVein
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AccuVein AV300, First Portable Vein Illumination Device, Now Available on GSA Schedule
2. Video: AccuVein Launches First Portable, Non-Contact Vein Illumination Device
3. RF Technologies Achieves Premier Certification From Cisco in United States
4. MediciGlobal Achieves Record Number of Awards
5. OH2 Medical Spa Achieves the First U.S. LEED(R) Certification for a Medical Commercial Interior
6. Journal of Alzheimers Disease once again achieves significant impact factor increase
7. Volcano Achieves Major Milestone in Japan Direct Sales Initiative With Signing of Termination Agreement With Goodman
8. OpusClinicalSuite(R) Achieves 08 CCHIT Certification as Inpatient EHR
9. IncentOne Achieves 2 Millionth Health Milestone
10. Misonix Subsidiary, Sonora Medical Systems, Achieves ISO 17025 Accreditation
11. InstaMed Achieves CAQH CORE Rules Certification, Streamlines Provider Access to Consistent Electronic Eligibility, Benefits and Patient Financial Liability Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... 2017 , ... Connecticut Dermatology Group (CDG) is proud and excited to welcome ... Dr. Kim brings an extensive background in cutting-edge dermatology care and research to ... welcome back Dr. Kim to the CDG team” said President and Managing Partner Dr. ...
(Date:1/19/2017)... ... , ... Sales Focus Inc. (SFI), a Maryland-based sales outsourcing company, announced today ... past 20 years SFI has been recognized as the world’s leader in Intelligent Sales ... the US market. The new clients include: Panacea Pro, Campseekers, Contentmart, Stress Pal, ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Infinity® Massage Chairs ... plan and implement new sales and marketing strategies. Grover comes with a total of ... 5 and a half years as Executive Vice President of Direct Sales at Traeger® ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... of Proctology) announced today the opening of 3 medical offices specializing specifically ... Hemorrhoids Center of Los Angeles (Beverly Hills), Hemorrhoids Center of Newport Beach, ...
(Date:1/18/2017)... ... 18, 2017 , ... A recent video posting of a new fidget product ... of fidgeting to relieve stress and anxiety. No one was more surprised than ... had just completed a successful Kickstarter campaign raising $67,000 on the popular crowdfunding platform. ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... PHILADELPHIA , Jan. 18, 2017 The Philadelphia ... three companies developing medical devices for children. The Consortium ... to receive seed grants of $50,000 each. The ... amplifies weak nerve signals, a hand-operated rapid blood delivery system ... ears in babies. ...
(Date:1/18/2017)... , Jan. 18, 2017   Regenicin, Inc. ... biotechnology company specializing in the development and commercialization of ... tissues and organs, recently reported the Company,s operating results ... 2017. As the Company described in its ... a year of substantial accomplishments. The Company,s contract laboratory ...
(Date:1/18/2017)... 2017  Dermata Therapeutics, LLC, a biotechnology company ... variety of dermatological diseases, announces dosing the first ... Phase 2 acne rosacea study. DMT210 is a ... cytokines in the skin responsible for the inflammation ... This clinical trial, DMT210-003, is a 12-week, ...
Breaking Medicine Technology: